Synaffix Announces Expansion of ADC Collaboration with MacroGenics
- MacroGenics adds up to four ADC programs
- MacroGenics may combine both its proprietary antibody and bispecific DART® technologies with Synaffix’s linker-payload technologies
- Expanded collaboration includes up to $2.2 billion in total potential payments plus tiered royalties on net sales
AMSTERDAM, NETHERLANDS, 14 March 2023, Synaffix B.V. (Synaffix), a biotechnology company focused on commercializing its clinical-stage platform technology for the development of antibody-drug conjugates (ADCs) with best-in-class therapeutic index, has announced the expansion of its license agreement with MacroGenics Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing and commercializing innovative monoclonal antibody-based therapeutics for the treatment of cancer.